About CircNova, Inc

This biotechnology company uses artificial intelligence to identify and analyze circular RNA for therapeutic development. Their platform focuses on non-coding RNA mechanisms to target previously undruggable diseases, enabling biopharmaceutical companies to develop novel treatments.

```xml <problem> Many diseases are considered "undruggable" due to the limitations of traditional drug discovery methods in targeting complex biological mechanisms. Current approaches often fail to address non-coding RNA's role in these diseases, leaving a significant gap in therapeutic development. There is a need for innovative methods to identify and analyze RNA structures for effective drug design. </problem> <solution> CircNova is a biotechnology company that leverages its AI NovaEngine™ to discover and analyze circular RNA (circRNA) for therapeutic development. The company's platform focuses on non-coding RNA mechanisms of action to target previously undruggable disease targets, addressing major unmet clinical needs. By using AI-guided RNA-folding and active structure prediction coupled with high-throughput RNA synthesis, CircNova enhances the efficiency of developing effective therapeutic candidates. The AI NovaEngine™ predicts circRNA structures using deep learning, enabling therapeutic design for diseases like Triple-negative Breast Cancer. </solution> <features> - AI NovaEngine™ for circRNA generation, analysis, and identification - Deep-learning algorithms for predicting circular RNA structures - AI-guided RNA-folding and active structure prediction - High-throughput RNA synthesis for efficient therapeutic candidate development - Focus on non-coding RNA with diverse mechanisms of action - Development of therapeutics for previously "undruggable" disease targets </features> <target_audience> CircNova's primary customers are biopharmaceutical companies seeking novel therapeutic targets and innovative drug discovery platforms, as well as research institutions focused on RNA-based therapeutics. </target_audience> ```

What does CircNova, Inc do?

How much funding has CircNova, Inc raised?

CircNova, Inc has raised 3300000.

Funding

3300000

Employees

9 employees

Major Investors

South Loop Ventures

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

CircNova, Inc

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

circnova.com 500+

Crunchbase

Funding

Estimated Funding

$3M+

Major Investors

South Loop Ventures

Team (5+)

No team information available.

Company Description

Problem

Many diseases are considered "undruggable" due to the limitations of traditional drug discovery methods in targeting complex biological mechanisms. Current approaches often fail to address non-coding RNA's role in these diseases, leaving a significant gap in therapeutic development. There is a need for innovative methods to identify and analyze RNA structures for effective drug design.

Solution

CircNova is a biotechnology company that leverages its AI NovaEngine™ to discover and analyze circular RNA (circRNA) for therapeutic development. The company's platform focuses on non-coding RNA mechanisms of action to target previously undruggable disease targets, addressing major unmet clinical needs. By using AI-guided RNA-folding and active structure prediction coupled with high-throughput RNA synthesis, CircNova enhances the efficiency of developing effective therapeutic candidates. The AI NovaEngine™ predicts circRNA structures using deep learning, enabling therapeutic design for diseases like Triple-negative Breast Cancer.

Features

AI NovaEngine™ for circRNA generation, analysis, and identification

Deep-learning algorithms for predicting circular RNA structures

AI-guided RNA-folding and active structure prediction

High-throughput RNA synthesis for efficient therapeutic candidate development

Focus on non-coding RNA with diverse mechanisms of action

Development of therapeutics for previously "undruggable" disease targets

Target Audience

CircNova's primary customers are biopharmaceutical companies seeking novel therapeutic targets and innovative drug discovery platforms, as well as research institutions focused on RNA-based therapeutics.